Concepedia

Mohamed Elmeliegy

ME

Statistics

Publications

24

Citations

2.3K

H-Index

16

Active since

2009

Affiliations

Pfizer (United States)(Current)

Novartis (Switzerland)

Saint Louis University

Huntsman Cancer Institute

University of Tennessee Health Science Center

Mohamed Elmeliegy is an author at Pfizer (United States) specializing in pharmacology, oncology, and medicine.

Publications per year

2009–2024

24

Publications

24

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

Gabriel N. Hortobágyi, Salomon M. Stemmer, H. A. Burris et al. · Annals of Oncology · 2018 · 868 citations · Full text

Medicine, Oncology, Pharmacology +17

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

Alexander M. Lesokhin, Michael H. Tomasson, Bertrand Arnulf et al. · Nature Medicine · 2023 · 564 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Role of ATP-Binding Cassette and Solute Carrier Transporters in Erlotinib CNS Penetration and Intracellular Accumulation

Mohamed Elmeliegy, Ángel M. Carcaboso, Michael Tagen et al. · Clinical Cancer Research · 2010 · 110 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Talazoparib in Patients with a Germline <i>BRCA</i>-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial

Sara A. Hurvitz, Anthony Gonçalvès, Hope S. Rugo et al. · The Oncologist · 2019 · 84 citations · Full text

Medicine, Oncology, Pharmacology +14

Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer

Neeraj Agarwal, Jean-Pascal Machiels, Cristina Suárez et al. · The Oncologist · 2016 · 81 citations · Full text

Medicine, Oncology, Pharmacology +15

1–5 of 24